Next Article in Journal
Ideas for Specific, Low-Power and Cost-Effective Chemical Sensors
Previous Article in Journal
The Cytotoxic Effects of Humic Acid on Human Breast Cancer Cells
Article Menu
Issue 25 (Cell Death 2018) cover image

Export Article

Open AccessProceedings
Proceedings 2018, 2(25), 1579; https://doi.org/10.3390/proceedings2251579

Combination of First Generation Proteasome Inhibitor Bortezomib with Temozolomide and Radiotherapy in Glioblastoma 2D and 3D Cell Cultures

1
School of Medicine/Genetic and Metabolic Diseases Research and Investigation Center, Marmara University, 34854 İstanbul, Turkey
2
Advanced Nanomaterials Research Laboratory, Marmara University, 34854 İstanbul, Turkey
3
Department of Radiation Oncology, School of Medicine, Marmara University, 34854 İstanbul, Turkey
Presented at the 2nd International Cell Death Research Congress, Izmir, Turkey, 1–4 November 2018.
*
Author to whom correspondence should be addressed.
Published: 7 December 2018
PDF [785 KB, uploaded 7 December 2018]

Abstract

Glioblastoma is the most common high-grade brain tumor in adults, which has a rapidly developing radiotherapy/chemotherapy resistance and high recurrence rate. The aim of our study is to determine the effects of bortezomib that is a quite important proteasome inhibitor on glioblastoma tumors in the 3D environment. In this study, we have performed bortezomib and temozolomide drug treatments and radiation applications to U251 cell line in 2D and 3D cultures with PCL/gelatin/graphene nanofibrous scaffolds. The best result was reached in the combination of drugs with radiation therapy that has the most decreased viability in the experiment group.
Keywords: glioblastoma; bortezomib; temozolomide; radiotherapy; 3D-culture glioblastoma; bortezomib; temozolomide; radiotherapy; 3D-culture
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Arslan, S.; Unal, S.; Gokce, T.; Atasoy, B.M.; Gunduz, O.; Karademir, B. Combination of First Generation Proteasome Inhibitor Bortezomib with Temozolomide and Radiotherapy in Glioblastoma 2D and 3D Cell Cultures. Proceedings 2018, 2, 1579.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Proceedings EISSN 2504-3900 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top